Interaction between hepatitis B virus replication and lipid metabolism in patients with chronic hepatitis B and NAFLD

Xiajie WEN; Guixin LI; Jie LI; Huiying RAO; Jidong JIA; Fengmin LU

doi:10.3969/j.issn.1001-5256.2021.07.002

Volume 37 Issue 7

Jul. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(7): 1495-1500

PDF( 1978 KB)

Interaction between hepatitis B virus replication and lipid metabolism in patients with chronic hepatitis B and NAFLD

DOI: 10.3969/j.issn.1001-5256.2021.07.002

1.
Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
2.
Institute of Hepatology, People's Hospital, Peking University, Beijing 100044, China
3.
Department of Infectious Diseases, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China
4.
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received Date: 2021-04-23
Accepted Date: 2021-04-23
Published Date: 2021-07-20

Abstract

Abstract

There is still a large number of patients with chronic hepatitis B virus (HBV) infection in China, which greatly affects the health of Chinese people. With the change in lifestyle, the incidence rate of nonalcoholic fatty liver disease (NAFLD) is increasing year by year in China. Some clinical studies have shown that there is a relatively low incidence rate of chronic HBV infection with NAFLD, while there are still reports on NAFLD in promoting the progression of chronic hepatitis B-related diseases. Based on literature search and review, this article attempts to investigate the interaction between HBV replication, abnormal lipid metabolism, and fatty liver disease in patients with chronic hepatitis B and NAFLD, in order to provide ideas for HBV antiviral treatment and prevention of NAFLD.
- Hepatitis B Virus,
- Hepatitis B,
- Non-alcoholic Fatty Liver Disease,
- Virus Replication

FullText(HTML)

References(51)

References

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
[3]	SHI JP, FAN JG, WU R, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J]. J Gastroenterol Hepatol, 2008, 23(9): 1419-1425. DOI: 10.1111/j.1440-1746.2008.05531.x.
[4]	JOO EJ, CHANG Y, YEOM JS, et al. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study[J]. Hepatology, 2017, 65(3): 828-835. DOI: 10.1002/hep.28917.
[5]	ZHONG GC, WU YL, HAO FB, et al. Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: A case-control study with propensity score analysis[J]. J Viral Hepat, 2018, 25(7): 842-852. DOI: 10.1111/jvh.12878.
[6]	WANG B, LI W, FANG H, et al. Hepatitis B virus infection is not associated with fatty liver disease: Evidence from a cohort study and functional analysis[J]. Mol Med Rep, 2019, 19(1): 320-326. DOI: 10.3892/mmr.2018.9619.
[7]	XU QH, JIE YS, SHU X, et al. Relationship of fatty liver with HBV infection, hyperlipidemia and abnormal alanine aminotransferase[J]. Chin J Exp Clin Virol, 2009, 23(2): 141-143. DOI: 10.3760/cma.j.issn.1003-9279.2009.02.022. 徐启桓, 揭育胜, 舒欣, 等. 脂肪肝与HBV感染、高脂血症及ALT异常的相关分析[J]. 中华实验和临床病毒学杂志, 2009, 23(2): 141-143. DOI: 10.3760/cma.j.issn.1003-9279.2009.02.022
[8]	DANE DS, CAMERON CH, BRIGGS M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis[J]. Lancet, 1970, 1(7649): 695-698. DOI: 10.1016/s0140-6736(70)90926-8.
[9]	YAN H, ZHONG G, XU G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. Elife, 2012, 1: e00049. DOI: 10.7554/eLife.00049.
[10]	WANG WX, LI M, WU X, et al. HNF1 is critical for the liver-specific function of HBV enhancer Ⅱ[J]. Res Virol, 1998, 149(2): 99-108. DOI: 10.1016/s0923-2516(98)80085-x.
[11]	LI M, XIE Y, WU X, et al. HNF3 binds and activates the second enhancer, ENⅡ, of hepatitis B virus[J]. Virology, 1995, 214(2): 371-378. DOI: 10.1006/viro.1995.0046.
[12]	CHEN M, HIENG S, QIAN X, et al. Regulation of hepatitis B virus ENI enhancer activity by hepatocyte-enriched transcription factor HNF3[J]. Virology, 1994, 205(1): 127-132. DOI: 10.1006/viro.1994.1627.
[13]	GUIDOTTI LG, EGGERS CM, RANEY AK, et al. In vivo regulation of hepatitis B virus replication by peroxisome proliferators[J]. J Virol, 1999, 73(12): 10377-10386. DOI: 10.1128/JVI.73.12.10377-10386.1999.
[14]	REESE VC, OROPEZA CE, MCLACHLAN A. Independent activation of hepatitis B virus biosynthesis by retinoids, peroxisome proliferators, and bile acids[J]. J Virol, 2013, 87(2): 991-997. DOI: 10.1128/JVI.01562-12.
[15]	TANG H, MCLACHLAN A. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism[J]. Proc Natl Acad Sci U S A, 2001, 98(4): 1841-1846. DOI: 10.1073/pnas.041479698.
[16]	BARDENS A, DÖRING T, STIELER J, et al. Alix regulates egress of hepatitis B virus naked capsid particles in an ESCRT-independent manner[J]. Cell Microbiol, 2011, 13(4): 602-619. DOI: 10.1111/j.1462-5822.2010.01557.x.
[17]	CHOU SF, TSAI ML, HUANG JY, et al. The dual role of an ESCRT-0 component HGS in HBV transcription and naked capsid secretion[J]. PLoS Pathog, 2015, 11(10): e1005123. DOI: 10.1371/journal.ppat.1005123.
[18]	JIANG B, HIMMELSBACH K, REN H, et al. Subviral hepatitis B virus filaments, like infectious viral particles, are released via multivesicular bodies[J]. J Virol, 2015, 90(7): 3330-3341. DOI: 10.1128/JVI.03109-15.
[19]	BREMER CM, BUNG C, KOTT N, et al. Hepatitis B virus infection is dependent on cholesterol in the viral envelope[J]. Cell Microbiol, 2009, 11(2): 249-260. DOI: 10.1111/j.1462-5822.2008.01250.x.
[20]	ABDUL-WAHED A, GUILMEAU S, POSTIC C. Sweet Sixteenth for ChREBP: Established roles and future goals[J]. Cell Metab, 2017, 26(2): 324-341. DOI: 10.1016/j.cmet.2017.07.004.
[21]	HAMILTON JA, KAMP F. How are free fatty acids transported in membranes? Is it by proteins or by free diffusion through the lipids?[J]. Diabetes, 1999, 48(12): 2255-2269. DOI: 10.2337/diabetes.48.12.2255.
[22]	LUO J, YANG H, SONG BL. Mechanisms and regulation of cholesterol homeostasis[J]. Nat Rev Mol Cell Biol, 2020, 21(4): 225-245. DOI: 10.1038/s41580-019-0190-7.
[23]	BOUCHARD MJ, SCHNEIDER RJ. The enigmatic X gene of hepatitis B virus[J]. J Virol, 2004, 78(23): 12725-12734. DOI: 10.1128/JVI.78.23.12725-12734.2004.
[24]	KIM K, KIM KH, KIM HH, et al. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha[J]. Biochem J, 2008, 416(2): 219-230. DOI: 10.1042/BJ20081336.
[25]	KIM KH, SHIN HJ, KIM K, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma[J]. Gastroenterology, 2007, 132(5): 1955-1967. DOI: 10.1053/j.gastro.2007.03.039.
[26]	KIM JY, SONG EH, LEE HJ, et al. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways[J]. J Mol Biol, 2010, 397(4): 917-931. DOI: 10.1016/j.jmb.2010.02.016.
[27]	PORSTMANN T, SANTOS CR, GRIFFITHS B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth[J]. Cell Metab, 2008, 8(3): 224-236. DOI: 10.1016/j.cmet.2008.07.007.
[28]	XIAO CX, YANG XN, HUANG QW, et al. ECHS1 acts as a novel HBsAg-binding protein enhancing apoptosis through the mitochondrial pathway in HepG2 cells[J]. Cancer Lett, 2013, 330(1): 67-73. DOI: 10.1016/j.canlet.2012.11.030.
[29]	OEHLER N, VOLZ T, BHADRA OD, et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism[J]. Hepatology, 2014, 60(5): 1483-1493. DOI: 10.1002/hep.27159.
[30]	SHLOMAI A, PARAN N, SHAUL Y. PGC-1alpha controls hepatitis B virus through nutritional signals[J]. Proc Natl Acad Sci U S A, 2006, 103(43): 16003-16008. DOI: 10.1073/pnas.0607837103.
[31]	CURTIL C, ENACHE LS, RADREAU P, et al. The metabolic sensors FXRα, PGC-1α, and SIRT1 cooperatively regulate hepatitis B virus transcription[J]. FASEB J, 2014, 28(3): 1454-1463. DOI: 10.1096/fj.13-236372.
[32]	KIM HY, CHO HK, KIM HH, et al. Oxygenated derivatives of cholesterol promote hepatitis B virus gene expression through nuclear receptor LXRα activation[J]. Virus Res, 2011, 158(1-2): 55-61. DOI: 10.1016/j.virusres.2011.03.010.
[33]	ZENG J, WU D, HU H, et al. Activation of the liver X receptor pathway inhibits HBV replication in primary human hepatocytes[J]. Hepatology, 2020, 72(6): 1935-1948. DOI: 10.1002/hep.31217.
[34]	DU L, MA Y, LIU M, et al. Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo[J]. Virol J, 2017, 14(1): 96. DOI: 10.1186/s12985-017-0765-x.
[35]	HU W, WANG X, DING X, et al. MicroRNA-141 represses HBV replication by targeting PPARA[J]. PLoS One, 2012, 7(3): e34165. DOI: 10.1371/journal.pone.0034165.
[36]	WAKUI Y, INOUE J, UENO Y, et al. Inhibitory effect on hepatitis B virus in vitro by a peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone[J]. Biochem Biophys Res Commun, 2010, 396(2): 508-514. DOI: 10.1016/j.bbrc.2010.04.128.
[37]	YOON S, JUNG J, KIM T, et al. Adiponectin, a downstream target gene of peroxisome proliferator-activated receptor γ, controls hepatitis B virus replication[J]. Virology, 2011, 409(2): 290-298. DOI: 10.1016/j.virol.2010.10.024.
[38]	ZHANG Z, PAN Q, DUAN XY, et al. Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model[J]. J Gastroenterol Hepatol, 2012, 27(12): 1858-1864. DOI: 10.1111/j.1440-1746.2012.07268.x.
[39]	HU D, WANG H, WANG H, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model[J]. Hepatol Int, 2018, 12(5): 438-446. DOI: 10.1007/s12072-018-9877-7.
[40]	LIN YL, SHIAO MS, METTLING C, et al. Cholesterol requirement of hepatitis B surface antigen (HBsAg) secretion[J]. Virology, 2003, 314(1): 253-260. DOI: 10.1016/s0042-6822(03)00403-3.
[41]	DOROBANTU C, MACOVEI A, LAZAR C, et al. Cholesterol depletion of hepatoma cells impairs hepatitis B virus envelopment by altering the topology of the large envelope protein[J]. J Virol, 2011, 85(24): 13373-13383. DOI: 10.1128/JVI.05423-11.
[42]	HORIE M, TSUCHIYA Y, HAYASHI M, et al. NB-598: A potent competitive inhibitor of squalene epoxidase[J]. J Biol Chem, 1990, 265(30): 18075-18078. http://europepmc.org/abstract/MED/2211682
[43]	TATEMATSU K, TANAKA Y, SUGIYAMA M, et al. Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B virus replication[J]. J Med Virol, 2011, 83(4): 587-593. DOI: 10.1002/jmv.21970.
[44]	ZHANG JY, DUAN ZP, ZHANG JL, et al. Research advances in the role of sphingolipids in HCV and HBV life cycles[J]. Chin J Hepatol, 2016, 24(12): 945-947. DOI: 10.3760/cma.j.issn.1007-3418.2016.12.016. 张金艳, 段钟平, 张金兰, 等. 鞘脂在HCV和HBV生命周期中作用的研究进展[J]. 中华肝脏病杂志, 2016, 24(12): 945-947. DOI: 10.3760/cma.j.issn.1007-3418.2016.12.016.
[45]	HUANG Q, LEI H, DING L, et al. Stimulated phospholipid synthesis is key for hepatitis B virus replications[J]. Sci Rep, 2019, 9(1): 12989. DOI: 10.1038/s41598-019-49367-8.
[46]	PARK ES, LEE JH, HONG JH, et al. Phosphatidylcholine alteration identified using MALDI imaging MS in HBV-infected mouse livers and virus-mediated regeneration defects[J]. PLoS One, 2014, 9(8): e103955. DOI: 10.1371/journal.pone.0103955.
[47]	HUANG H, SUN Z, PAN H, et al. Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B[J]. Sci Rep, 2016, 6: 30853. DOI: 10.1038/srep30853.
[48]	LI H, ZHU W, ZHANG L, et al. The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment[J]. Sci Rep, 2015, 5: 8421. DOI: 10.1038/srep08421.
[49]	GAVILANES F, GONZALEZ-ROS JM, PETERSON DL. Structure of hepatitis B surface antigen. Characterization of the lipid components and their association with the viral proteins[J]. J Biol Chem, 1982, 257(13): 7770-7777. http://www.ncbi.nlm.nih.gov/pubmed/7085648
[50]	OKAMURA H, NIO Y, AKAHORI Y, et al. Fatty acid biosynthesis is involved in the production of hepatitis B virus particles[J]. Biochem Biophys Res Commun, 2016, 475(1): 87-92. DOI: 10.1016/j.bbrc.2016.05.043.
[51]	ESSER K, LUCIFORA J, WETTENGEL J, et al. Lipase inhibitor orlistat prevents hepatitis B virus infection by targeting an early step in the virus life cycle[J]. Antiviral Res, 2018, 151: 4-7. DOI: 10.1016/j.antiviral.2018.01.001.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	张明. 酒精性肝病合并乙型肝炎病毒感染病例临床分析. 中国医药指南. 2024(02): 114-116 .
2.	吴琦玮，高杨，李艳辉，沈榕. 2015—2019年北京地区乙型肝炎疾病负担及趋势预测分析. 实用预防医学. 2024(11): 1349-1352 .
3.	董丹丹，邱利，胡毅. 慢性HBV感染合并非酒精性脂肪性肝病患者血清脂联素、ROS及糖脂代谢特征. 肝脏. 2024(10): 1265-1268+1273 .
4.	毛垚耀，何惠昌，谢露，崔健娇，刘光伟. 健脾活血解毒方联合恩替卡韦对乙型病毒性肝炎合并非酒精性脂肪性肝病小鼠的干预作用及机制. 现代中西医结合杂志. 2023(08): 1047-1052 .
5.	沈从乐，李韦杰，任博，孙继云，王雅杰. 2543例不同病因慢性肝病糖脂代谢异常率分析. 标记免疫分析与临床. 2022(09): 1451-1454 .
6.	倪盟，曾雷. miRNA单核苷酸多态性与HBV感染相关疾病关系的研究进展. 吉林大学学报(医学版). 2021(06): 1588-1593 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2032) PDF downloads(382)

Interaction between hepatitis B virus replication and lipid metabolism in patients with chronic hepatitis B and NAFLD

DOI: 10.3969/j.issn.1001-5256.2021.07.002